Berhanu Kibret

Berhanu Kibret

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BKBerhanu Kibret
Berhanu Kibret
HIHiroki Ishiguro
Hiroki Ishiguro
YHYasue Horiuchi
Yasue Horiuchi
EOEmmanuel Onaivi
Emmanuel Onaivi
The endocannabinoid system (ECS) is ubiquitous in most human tissues, and involved in the regulation of mental health. Consequently, its dysregulation is associated with neuropsychiatric and neurodegenerative disorders. Together, the ECS and the expanded endocannabinoidome (eCBome) are composed of genes coding for CB1 and CB2 cannabinoid receptors (CB1R, CB2R), endocannabinoids (eCBs), and the metabolic enzyme machinery for their synthesis and catabolism. The activation of CB1R is associated with adverse effects on the central nervous system (CNS), which has limited the therapeutic use of drugs that bind this receptor. The discovery of the functional neuronal CB2R raised new possibilities for the potential and safe targeting of the ECS for the treatment of CNS disorders. Previous studies were not able to detect CB2R mRNA transcripts in brain tissue and suggested that CB2Rs were absent in the brain and were considered peripheral receptors. Studies done on the role of CB2Rs as a potential therapeutic target for treating different disorders revealed the important putative role of CB2Rs in certain CNS disorders, which requires further clinical validation. This review addresses recent advances on the role of CB2Rs in neuropsychiatric and neurodegenerative disorders, including, but not limited to, anxiety, depression, schizophrenia, Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD) and addiction.

25 August 2016 in BMC Public Health
Verified
Journal Article
Open access
PDF file
YBYeshiwork Beyene
Yeshiwork Beyene
BKBerhanu Kibret
Berhanu Kibret
AMAssefa Mulu
Assefa Mulu
In high human immunodeficiency virus (HIV) prevalence population, tuberculosis (TB) is the leading cause of morbidity and mortality. HIV is driving the TB epidemic in many countries, especially those in sub-Saharan Africa. We assessed the survival time and predictors of mortality among tuberculosis patients under directly observed treatment, short course (DOTS) strategy in Dessie Referral Hospital tuberculosis clinic, Northeast Ethiopia. A historical cohort design was utilized to assess survival time and determinants of mortality. A total of 1260 records of patients who started ant-tuberculosis treatment from January 2006 up to December 2010 were analyzed. Survival curves were estimated using Kaplan–Meier and were compared using the Log-rank test. The Cox proportional hazard model was used to assess the relationship between baseline variables and mortality. Out of the 1260 registered patients, 117 (9.3 %) died over the entire follow-up period. Among those died, 113 (18 %) were HIV positive and 4 (0.6 %) were HIV negative. The 1260 patients contributed a cumulative total of 634.25 person‑years observation. The mortality of HIV positive tuberculosis patients was higher than those of HIV negative patients and the use of cotrimoxazole preventive therapy increased the survival time of patients.

1 November 2015 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
BKBerhanu Kibret
Berhanu Kibret

1 October 2016 in Brain Research
Verified
Journal Article
Closed access
BKBerhanu Kibret
Berhanu Kibret
EOEmmanuel Onaivi
Emmanuel Onaivi
EEEphrem Engidawork
Ephrem Engidawork

1 January 2015 in International Journal of Basic & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
AMAssefa Mulu
Assefa Mulu
BKBerhanu Kibret
Berhanu Kibret
YBYeshiwork Beyene
Yeshiwork Beyene
MAMuluneh Ademe
Muluneh Ademe
Background: The impact of resistance to antimalarials is insidious and unless efficacy studies are conducted, resistance may go unrecognized. The aim of this study was to assess the efficacy of artemether/lumefantrine, for the treatment of uncomplicated Plasmodium falciparum infections in Kemisie Health Center, Northeast Ethiopia.Methods: Artemether/lumefantrine efficacy study was conducted in Kemisie Health Center, Northeast Ethiopia from September, 2012 to May, 2013. The study participants were febrile people above the age of 6 months with confirmed uncomplicated P. falciparum infection. Patients were treated with artemether/lumefantrine. Clinical and parasitological parameters were monitored over a 28 days follow-up period to evaluate drug efficacy. The Kaplan–Meier method was used for statistical analysis of data on drug efficacy.Results: Among the 66 enrolled participants 72.7% were 15 and above years of age while 15.3% were less than 5 years old. Of these study participants, 53% were male. There was 89.4% fever clearance and 84.8% parasite clearance on day 1, whereas, there was 100% fever clearance and 96.8% parasite clearance on day 3 from the 62 participants who carried on the study. Among 66 participants who had started 28 days of follow-up one patient had an early parasitological failure (parasitemia on day 3) and another patient had a late parasitological failure (parasitemia on day 21).Conclusions: In general, this study discovered good clinical and parasitological response of P. falciparum to artemether/lumefantrine. Further polymeric chain reaction and plasma drug concentration based effectiveness study of artemether/lumefantrine should be conducted throughout the country.

22 August 2017 in African Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
PDF file
KBKassa Belete
Kassa Belete
MAMulu Adugnaw
Mulu Adugnaw
BKBerhanu Kibret
Berhanu Kibret
Adverse drug reaction (ADR) is a noxious and undesirable reaction to drugs at dosage normally used in humans for diagnosis, treatment or prophylaxis of diseases or ailments. Spontaneous reporting is currently the major back bone for the detection of adverse drug reactions. The objective of the study was to assess the knowledge, attitude, and practice of health professionals towards ADR reporting in Boru Meda Hospital, North East Ethiopia. A quantitative cross-sectional study design was used. A self-administered questionnaire was used to collect data from the health professionals, and the collected data was analyzed using SPSS (version 16). A test of association for selected variables was done using Pearson chi–square. From a total of 57 respondents, 40 (70.1%) were able to differentiate ADR from side effects. Thirty six (63.2%) and 34 (59.6%) respondents knew the availability of national reporting system and ADR reporting form in Ethiopia, respectively. Majority, 46 (80.7%), of the respondents said that ADR should be reported only when they are serious and life threatening. Out of 12 respondents who encountered ADR in the past 12 months in their clinical activities, 10 reported to responsible body. Health professionals working in Boru Meda Hospital have good attitude towards ADR reporting and good reporting culture of encountered ADRs, but insufficient knowledge about ADRs. The unavailability of ADR reporting forms take the lions part in significantly discouraging them to detect and report ADRs. Key words: Adverse drug reactions, knowledge, attitude, practices, health professionals, pharmacovigilance, Boru Meda Hospital.